Table 2.
Toxicity and treatment outcomes.
| Characteristics | Pts./Events/Percentage | |
|---|---|---|
| Toxicity (CTCAE grade) | ||
| ECT-related | 0 | |
| Non-ECT-related within 24 h | 0 | |
| Non-ECT-related after 24 h | 4 (16.7%) | |
| Postoperative complications (up to 30 days after ECT) according to Clavien-Dindo Classification | ||
| Grade I | 11 (46%) | |
| Grade II | 2 (8%) | |
| Grade III | 2 (8%) | |
| Response to ECT/tumor (RECIST v1.1) | ||
| Number of tumors | 32 | |
| CR | 27 (84.4%) | |
| PR | 4 (12.5%) | |
| SD | 1 (3.1%) | |
| PD | 0 (0%) | |
| Response to ECT/patient (RECIST v1.1) | ||
| Number of patients | 24 | |
| CR | 19 (79.2%) | |
| PR | 4 (16.6%) | |
| SD | 1 (4.2%) | |
| PD | 0 (0%) | |
| Response according to tumor location | Central | Peripheral |
| Number of tumors | 11 (34.4%) | 21 (65.6%) |
| CR | 9 (81.8%) | 18 (85.7%) |
| PR | 1 (9.1%) | 3 (14.3%) |
| SD | 1 (9.1%) | 0 (0%) |
| Response according to tumor size | ≤3 cm diameter | >3 cm diameter |
| Number of tumors | 24 (75%) | 8 (25.0%) |
| CR | 22 (91.7%) | 5 (62.5%) |
| PR | 2 (8.3%) | 2 (25.0%) |
| SD | 0 (0%) | 1 (12.5%) |
CR—Complete Response, PR—Partial Response, SD—Stable Disease, PD—Progressive Disease.